期刊文献+

达比加群酯的合成工艺改进 被引量:11

Improved synthesis of dabigatran etexilate
原文传递
导出
摘要 目的改进达比加群酯的合成工艺,提高反应收率并简化操作。方法以4-甲胺基-3-硝基苯甲酸为原料,与3-(吡啶-2-基氨基)丙酸乙酯缩合后,经催化氢化、酰胺化后闭环、成脒、与氯甲酸正己酯反应得到达比加群酯。结果与结论目标化合物的结构经核磁共振氢谱、质谱确证。改进后的合成方法与原工艺相比,环境友好,收率提高了16.4%,总收率为33.75%(以4-甲胺基-3-硝基苯甲酸计)。 Dabigatran etexilate,an oral direct thrombin inhibitor(DTI),is an effective drug for thromboembolic diseases.A new economical and environmental friendly synthetic method was developed.Firstly,4-(methylamino)-3-nitrobenzoic acid was reacted with ethyl 3-(pyridin-2-ylamino)propanoate(2) under the catalysis of 2-chloro-1-methylpyridinium iodide(CMPI) to give ethyl 3-[4-(methylamino)-3-nitro-N-(pyridin-2-yl)benzamido] propanoate(4),4 was reduced to get ethyl 3-[3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido] propanoate(5),then 5 was reacted with 2-(4-cyanophenylamino)acetic acid(6) to get ethyl 3-{2-[(4-cyanophenylamino)methyl]-1-methyl-N-(pyridin-2-yl)-1H-benzoimidazole-5-carboxamido}propanoate(7),7 was reacted with hydroxylamine hydrochloride then reduced in the presence of HCOONH4 and Pd/C to get ethyl 3-{2-[(4-carbamimidoyl-phenylamino)methyl]-1-methyl-N-(pyridin-2-yl)-1H-benzoimidazole-5-carboxamido}propanoate(8),finally,8 was reacted with hexyl carbonochloridate(9) to afford dabigatran etexilate(1).The overall yield was about 33.75%,which increased by 16.4% based on 4-(methylamino)-3-nitrobenzoic acid.The chemical structure of dabigatran etexilate was characte-rized by MS,1H-NMR.Compared with the original synthetic process,the new route is facile and suitable for industrialized production with lower pollution and higher yield.
出处 《中国药物化学杂志》 CAS CSCD 2012年第3期204-208,共5页 Chinese Journal of Medicinal Chemistry
关键词 工艺改进 化学合成 达比加群酯 process improvement chemical synthesis dabigatran etexilate
  • 相关文献

参考文献6

  • 1宫平,贾薇.新型口服抗凝血药物达比加群酯[J].世界临床药物,2008,29(9):544-547. 被引量:26
  • 2Brain D.J,David GAllen, et al.A versatile synthesis of amidines from nitriles via midoximes, synthetic communications[]..1996
  • 3NH Hauel,H Nar,H Priepke,U Ries,JM Stassen,W Wienen.Structure-based design of novel potent nonpeptide thrombin inhibitors[].Journal of Medicinal Chemistry.2002
  • 4GERALD R L.Cyclization of 2-aminopyridine deri-vatives.Ⅲ.Reaction of some 2-aminopyridines withalkyl acrylates and alkyl 3-halopropionates[].Journal of Inorganic Chemistry USSR.1958
  • 5TAKASHI F.Substituted pyrazinecarboxylic acid ani-lide derivatives or salts thereof,intermediates of thesame,pesticides for agricultural and horticultural use,and usage thereof[].US A.2008
  • 6MARIAPPAN A,DAVID W B,CHARD E.Directconversion of amidoximes to amidines via transfer hy-drogenation stephens[].Synthesis.2003

二级参考文献10

  • 1Hauel NH,Nar H,Priepke H,et al.Structure-based design of novel potent nonpeptide thrombin inhibitors[].Journal of Medicinal Chemistry.2002
  • 2Wienen W,Stassen JM,Priepke H,et al.Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabigatran etexilate,on thrombus formation and bleeding time in rats[].Thrombosis and Haemostasis.2007
  • 3Wienen W,Stassen JM,Priepke H,et al.In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabigatran etexilate[].Thrombosis and Haemostasis.2007
  • 4Stangier J,Eriksson BI,Dahl OE,et al.Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement[].Journal of Clinical Pharmacology.2005
  • 5Troconiz IF,Tillmann C,Liesenfeld KH,et al.Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate(BIBR 1048) in patients undergoing primary elective total hip replacement surgery[].Journal of Clinical Pharmacology.2007
  • 6Blech S,Ebner T,Ludwig-Schwellinger E,et al.The metabolism and disposition of the oral direct thrombin inhibitor,dabigatran,in humans[].Drug Metabolism and Disposition.2008
  • 7Eriksson BI,Dahl OE,Ahnfelt L,et al.Dose escalating safety study of a new oral direct thrombin inhibitor,dabigatran etexilate,in patients undergoing total hip replacement:BISTRO Ⅰ[].Journal of Thrombosis and Haemostasis.2004
  • 8Wienen,W,Stassen,JM,Priepke,H.Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis[].Journal of Thrombosis and Haemostasis.2007
  • 9Eriksson,BI,Dahl,OE,Buller,HR.A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial[].Journal of Thrombosis and Haemostasis.2005
  • 10Eriksson B I,Dahl O E.Oral dabigatran etexilate vs.subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:the RE-MODEL randomized trial[].Journal of Thrombosis and Haemostasis.2007

共引文献25

同被引文献85

  • 1Lee W M,Larrey D,Olsson R,et al.Hepatic findings in long-term clinical trials ofximelagatran.Drug Saf,2005,28(4):351-370.
  • 2Blech S,Ebner T,Ludwig-Schwellinger E,et al.The metabolism and disposition of the oral direct thrombin inhibitor,dabigatran,in humans.Drug MetabDispos,2008,36(2):386-399.
  • 3Wienen W,Stassen J M,Priepke H,et al.In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabig,atran etexilate.Thromb Haemost,2007,98(1):155-162.
  • 4Serra M J,Duran L E,et al.Dabigatran etexilate and related substances,processes and compositions,and use of the substances as reference standards and markers.EP,2522662(A1)[P].2011-05-11.
  • 5Hauel NH,Nar H,Priepke H,et al.Structure-based design of novel potent nonpeptide thrombin inhibitors[J].J Med Chem,2002,45(9):1757-1766.
  • 6Jirman j,Richter J,Lustig P.A method for the manufacture of dabigatran.WO,2009111997(A1)[P].2008-03-14.
  • 7Segade R A,Pasto A M.Process of preparation of a thrombin specific inhibitor.WO,2012004396(A2)[P].2010-07-09.
  • 8Zentiva K S,Lustig P,Jirman J.A method for the preparation of dabigatran and its intermediates.WO,2010045900(A1)[P].2008-10-24.
  • 9Satyanarayana R M,Nagaraju C,Thirumalai R S,et al.Process for the preparation of benzimidazole derivatives and its salts.WO,2012077136(A2)[P].2011-12-07.
  • 10Kiraly I,Szabo T,Simig G,et al.Process for the manufcture of dabigatran etexilate and inermediates thereof.WO,2012153158(A1)[P].2011-05-11.

引证文献11

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部